European Health Examination Survey

Title of the cohort
European Health Examination Survey
Acronym for cohort
LUX-EHES
Name of Principal Investigator

Title mme
First name  Marie-Lise
Last name LAIR

Address of institution where award is held

Institution
Street Address 1A-B rue Thomas Edison
City SRASSEN
Postcode L-1445

Country
Luxembourg
Website
www.crp-sante.lu
Contact email
[email protected]
Funding source
Health Ministry
Research Ministry
1. The cohort includes, or expects to include, incidence of the following conditions

  • Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible
2011 – 2015
2a. Stated aim of the cohort
to study public health determinants
2b. Features distinguishing this cohort from other population cohorts
we ask blood sample for biobanking
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort
epdemiological informations public health informations impact of environmental conditions on health and some diseases
4a. Study criteria: age range of participants at recruitment

Age in years from: more 18 years
To (‘until death’ if applicable): 65 years

4b. Study criteria: inclusion criteria
criteria from european health examination survey will be used. People will be randomly selected from the national register.
4c. Study criteria: exclusion criteria
institutionalised people
5. Size of the cohort (i.e. number of participants enrolled)
5,001 – 10,000 participants
6a. Measures used to characterise participants
age, gender, comorbidities, socio economic conditions, socio educative conditions, environmental conditions, lifestyle (tobacco, nutrition, alcoohol, physical activity), medications, diseases, health status, family diseases, use of healthcare, ethnical informations, work conditions, vaccines, anthropometric measurements, blood pressure, blood analysis, visual capacity, auditiv capacity, cognitiv status
6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
No
7. Study design
Cross sectional survey
8. Cases matched by

  • Age
  • Sex
  • Co-morbidities
  • Cognitive function
  • Physical ability

9a. Does the study include a specialised subset of control participants
No
9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-01-2012
10a. ii) Data collection end date
31-12-2013
10a iii) Data collection for this study is

  • At the planning stage

10b. Plans to continue the cohort study beyond the current projected end date

  • Yes – intend to apply for funding

11. Data collected

  • Only through the study

12. System in place to enable re-contact with patients for future studies
Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database  yes
Database is web-based  yes
Database on spreadsheet
Database is on paper
Other (specify)

Language used:
french, german, english, portuges
13b. Format and availability of data held as individual records

Language used:

14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups

  • Apply to PI or co-ordinator at resource
  • Access through collaboration with PI only
  • Access Committee mechanism
  • Local/ regional access
  • National access
  • International access
  • Access restricted to peer-reviewed work
  • Applicant needs to provide separate external ethics approval

15. Data sharing policy specified as a condition of use
Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA

  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
No

European Health Examination Survey

Population Cohorts
Luxembourg
Neurodegenerative disease in general

 

 

Post
Filter